← Research library

Suprefort with and without Cerluten and Endoluten in type 2 diabetes

Comparison in people · 2013

What was studied
918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.
Main finding
The conference report lists two-hour glucose of 9.7 mmol/L with standard care, 7.3 with added Suprefort, and 6.5 with the three-product combination.

Glucose two hours after challenge · 9.7 ± 0.5 mmol/L with standard care, 7.3 ± 0.6 with added Suprefort, 6.5 ± 0.4 with the three-product combination. · Both adjunctive arms are marked significant versus standard care. Exact p values are unavailable.

Reported findings and study design

Moscow, February 2011 to April 2012. Standard treatment alone (329), plus Suprefort (214), or plus Suprefort, Cerluten and Endoluten (375). Suprefort and Cerluten were given orally as two capsules each per day for three months. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified in this source.

Population or model 918 adults aged 52–65 with type 2 diabetes: 329 standard care, 214 added Suprefort, 375 added Suprefort, Cerluten and Endoluten.

Results · Russian conference reproduction, pp. 11–13, and matching English edition
MeasureResultComparison, timing and statistics
Glucose two hours after challenge9.7 ± 0.5 mmol/L with standard care, 7.3 ± 0.6 with added Suprefort, 6.5 ± 0.4 with the three-product combination.Both adjunctive arms are marked significant versus standard care. Exact p values are unavailable.
Fasting glucose6.8 ± 0.6, 6.1 ± 0.5 and 5.6 ± 0.4 mmol/L, respectively.Both adjunctive arms are marked significant versus standard care.
Standard medication dose reportedly reduced0/329 standard care, 114/214 (53.3%) added Suprefort, 279/375 (74.4%) three-product combination.Medication-adjustment criteria and timing are unspecified.
Glucose response countsSuprefort arm: 195/214 (91.1%) reached the reported upper normal limit by day 18. Three-product arm: 348/375 (92.8%) reportedly normalized by day 12.These outcomes use different assessment days and wording.
Blood glucose in the three reported groups
Blood glucose in the three reported groups
Treatment groupParticipantsFasting beforeFasting afterTwo-hour beforeTwo-hour after
Standard care3298.4 ± 0.66.8 ± 0.613.8 ± 0.49.7 ± 0.5
Standard care + Suprefort2148.2 ± 0.76.1 ± 0.513.4 ± 0.67.3 ± 0.6
Standard care + Suprefort, Cerluten and Endoluten3758.3 ± 0.75.6 ± 0.413.6 ± 0.66.5 ± 0.4

Glucose in mmol/L. Table 3 leaves the timing and the meaning of the ± term unspecified.

The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. The reports do not give a systematic harms assessment. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Source for these results ↗ · Reviewed 2026-11-16

Study limitations and source details

Study limitations

  • Allocation, masking, treatment adjustments, exact timing of Table 3 and analysis denominators are unspecified. The response counts use different assessment days.
  • The 918-person Moscow comparison has a different site and design from the 59-person St. Petersburg Medical Center report. Participant-level linkage is unavailable.
  • The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.

Source details

Conference report · company reproduction

Authors’ conference material, Russian reproduction, PDF pages 11–13, methods and Table 3. English and Russian editions describe the same cohort.

Sources checked

Citation

Human comparative studyRussian-language source

D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov. Suprefort with and without Cerluten and Endoluten in type 2 diabetes 20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides.

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards